Cubist Systematic Strategies LLC Takes Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Cubist Systematic Strategies LLC acquired a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 25,987 shares of the company’s stock, valued at approximately $152,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its position in shares of Olema Pharmaceuticals by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 332,950 shares of the company’s stock valued at $1,941,000 after acquiring an additional 2,189 shares during the period. Boothbay Fund Management LLC increased its position in shares of Olema Pharmaceuticals by 10.8% in the 4th quarter. Boothbay Fund Management LLC now owns 31,226 shares of the company’s stock valued at $182,000 after acquiring an additional 3,056 shares during the period. Virtus ETF Advisers LLC increased its position in shares of Olema Pharmaceuticals by 43.1% in the 4th quarter. Virtus ETF Advisers LLC now owns 10,579 shares of the company’s stock valued at $62,000 after acquiring an additional 3,185 shares during the period. SG Americas Securities LLC increased its position in shares of Olema Pharmaceuticals by 33.8% in the 4th quarter. SG Americas Securities LLC now owns 17,475 shares of the company’s stock valued at $102,000 after acquiring an additional 4,419 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Olema Pharmaceuticals in the 4th quarter valued at $30,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Stock Performance

Shares of OLMA opened at $4.71 on Monday. The business’s 50-day moving average is $4.29 and its two-hundred day moving average is $6.04. The company has a market capitalization of $321.98 million, a P/E ratio of -2.15 and a beta of 2.03. Olema Pharmaceuticals, Inc. has a fifty-two week low of $2.86 and a fifty-two week high of $16.62.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.13. Analysts forecast that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current year.

Analyst Upgrades and Downgrades

OLMA has been the topic of several research reports. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a research report on Monday, April 28th. Oppenheimer cut their target price on Olema Pharmaceuticals from $25.00 to $22.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 14th. JPMorgan Chase & Co. cut their price target on Olema Pharmaceuticals from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Friday, March 28th. Finally, The Goldman Sachs Group cut their price target on Olema Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.